CD274 (PD-L1), exploited by tumors to attenuate anti-tumor immunity, was strongly upregulated in the tumor (log2 ratio, 4.1), suggesting that anti-PD-1/PD-L1 therapy might be sufficient for this patient. This evidence concerns the gene CD274 and neoplasm.